Contrasting Sophiris Bio (OTCMKTS:SPHS) and Xilio Therapeutics (NASDAQ:XLO)

Sophiris Bio (OTCMKTS:SPHS) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Profitability

This table compares Sophiris Bio and Xilio Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sophiris Bio	N/A	N/A	N/A
Xilio Therapeutics	N/A	-211.50%	-80.31%

Earnings and Valuation

This table compares Sophiris Bio and Xilio Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sophiris Bio	N/A	N/A	N/A	N/A	N/A
Xilio Therapeutics	$9.27 million	3.79	-$76.40 million	($0.84)	-0.81

Sophiris Bio has higher earnings, but lower revenue than Xilio Therapeutics.

Volatility & Risk

Sophiris Bio has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Sophiris Bio and Xilio Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sophiris Bio	0	0	0	0	0.00
Xilio Therapeutics	0	0	1	0	3.00

Xilio Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 489.71%. Given Xilio Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Xilio Therapeutics is more favorable than Sophiris Bio.

Insider and Institutional Ownership

54.3% of Xilio Therapeutics shares are owned by institutional investors. 4.5% of Sophiris Bio shares are owned by insiders. Comparatively, 5.2% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Xilio Therapeutics beats Sophiris Bio on 6 of the 9 factors compared between the two stocks.

About Sophiris Bio

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.

About Xilio Therapeutics

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.